PhD Scientific Days 2026

Theoretical and Translational Medicine 3.

Prospective Study on the Immune Function-Related Cytokine Profile of NSCLC patients treated with First-line Chemo-immunotherapy Combinations

Előadó neve

Vágó-Szincsák, Sára

Neptune code

H1ZP61

Előadó munkahelye

Semmelweis University, Institute of Clinical Pathophysiology

Előadó telefonszáma

06203335216

Előadó e-mail címe

szincsak.sara@gmail.com

Az előadás címe

Prospective Study on the Immune Function-Related Cytokine Profile of NSCLC patients treated with First-line Chemo-immunotherapy Combinations

Szerző(k) neve és munkahelye

Sára Szincsák¹, Péter Király², Ágnes Kemény³, Gabriella Gálffy², Zoltán Lohinai⁴

1: Institute of Clinical Pathophysiology, Semmelweis University
2: Reformed Pulmonology Center
3: Department of Physiology and Biochemistry, University of Veterinary Medicine
4: Reformed Pulmonology Center, Institute of Clinical Pathophysiology, Semmelweis University

Bemutatás módja

Szóbeli

Szekció

Theoretical and Translational Medicine 3.

Language of the presentation

English

Preferred session

Theoretical and Translational Medicine

Összefoglaló szövege

Introduction: The application of chemo-immunotherapy in non-small cell lung cancer (NSCLC) has significantly improved patient survival over the past decade. Aims: Our objective was to assess the immune function-related cytokine profile of NSCLC patients according to long vs short survival.Methods: Between 25 September 2024 and 18 March 2026, we conducted a prospective study at the Reformed Pulmonology Center (Törökbálint) involving 39 patients with NSCLC treated with first-line chemo-immunotherapy combinations. We stratified patients according to long (>10 months) and short (≤10 months) progression-free survival (PFS). We investigated pre-treatment plasma samples from 39 patients using a multiplex ELISA assay targeting 45 immune-related cytokines, chemokines, and growth factors.Results: The study included 20 female and 19 male patients. Adenocarcinoma was diagnosed in 28 patients, squamous cell carcinoma in 9, and NSCLC (not otherwise specified) in 2 cases. High (>50%) tumoural Programmed Death-Ligand 1 (PD-L1) expression was observed in 33 patients (53%). COPD comorbidity was present in 13 patients (33%). The most significant difference between the two groups in pre-treatment plasma was observed for IL-2 (long PFS/short PFS, p=0.0014) and IL-5 (long PFS/short PFS, p=0.0013), concentrations were elevated for short survival. Conclusion: Our findings support the importance of the immune milieu in the efficacy of chemo-immunotherapy in non-small cell lung cancer. Consideration of immune status is essential when developing a treatment strategy Funding: This study was supported by the Semmelweis 250+ Excellence PhD Scholarship.
szincsak.sara@gmail.com
Semmelweis University
Dr. Lohinai Zoltán

University

Semmelweis University

Supervisor

Dr. Lohinai Zoltán

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies after complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem hagyta jóvá

Előadó

7486

Start

12:00

End

12:10